PF-07062119

N/A

Report date: 2026/03/19 17:15:06

Base Information

Drug NamePF-07062119

Drug Alias NamePF-07062119

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionHeat-stable enterotoxin receptor antagonistsT cell surface glycoprotein CD3 stimulants

TargetsHeat-stable enterotoxin receptorT cell surface glycoprotein CD3

Therapy Area/IndicationsLarge intestine neoplasmStomach NeoplasmsGastrointestinal Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsLarge intestine neoplasmStomach NeoplasmsGastrointestinal Neoplasms +[4]

Other Information

ATC CodeN/A